Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.03. | Galecto Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
08.03. | Galecto, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
08.03. | Galecto, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
22.01. | GB-2064 by Galecto for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval | 2 | Pharmaceutical Technology | ||
22.01. | GB-2064 by Galecto for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval | 3 | Pharmaceutical Technology | ||
22.12.23 | Galecto posts myelofibrosis data as search for savior continues, investors shrug | 1 | FierceBiotech | ||
21.12.23 | Galecto stock rallies 25% on positive data for myelofibrosis drug | 3 | Seeking Alpha | ||
21.12.23 | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
21.12.23 | Galecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis | 299 | GlobeNewswire (Europe) | BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced... ► Artikel lesen | |
07.11.23 | Galecto Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
06.11.23 | Galecto, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
23.10.23 | Galecto, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.10.23 | Galecto, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.09.23 | Galecto, Inc.: Galecto Announces Plans to Explore Strategic Alternatives | 391 | GlobeNewswire (Europe) | BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced... ► Artikel lesen | |
15.08.23 | Galecto, Inc.: Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis | 238 | GlobeNewswire (Europe) | BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments... ► Artikel lesen | |
31.07.23 | Galecto, Inc.: Galecto Reports Second Quarter Operating and Financial Results | 349 | GlobeNewswire (Europe) | BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for... ► Artikel lesen | |
28.04.23 | Galecto, Inc.: Galecto Reports First Quarter Operating and Financial Results | 385 | GlobeNewswire (Europe) | BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,860 | -0,80 % | EQS-News: Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023 | EQS-News: Epigenomics AG
/ Schlagwort(e): Jahresergebnis/Jahresbericht
Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023
14.03.2024 / 08:00 CET/CEST
Für... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 1,185 | +1,72 % | Raus aus BioNTech und rein in Defence Therapeutics und Evotec Aktie? | Bei der BioNTech-Aktie ist derzeit die Luft raus. Obwohl sich die Stimmung im Sektor verbessert, so ist Star-Investorin Cathie Wood kürzlich bei Moderna eingestiegen, kommt der deutsche Biotech-Primus... ► Artikel lesen | |
GINKGO BIOWORKS | 1,180 | +6,79 % | AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production | ||
BEAM THERAPEUTICS | 33,060 | -2,54 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,975 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX
Impressive objective response... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 9,990 | -2,44 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
ARCTURUS THERAPEUTICS | 33,550 | +2,19 % | Arcturus COO sells shares worth nearly $300k | ||
ASSERTIO | 0,956 | -4,45 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
SIGA TECHNOLOGIES | 8,495 | +0,77 % | Dividendenbekanntmachungen (25.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,999 USD 0,9242 EUR ABB LTD ADR US0003752047 0,9993 USD 0,9245 EUR ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0... ► Artikel lesen | |
MERRIMACK PHARMACEUTICALS | 14,750 | -0,03 % | MERRIMACK PHARMACEUTICALS INC - 8-K, Current Report | ||
VIR BIOTECHNOLOGY | 10,115 | -0,64 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
BIO-PATH | 4,030 | -1,95 % | BIO-PATH HOLDINGS INC - 8-K, Current Report | ||
VERVE THERAPEUTICS | 13,340 | +2,14 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
ARS PHARMACEUTICALS | 10,300 | +4,41 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results | Preparing to submit response to the FDA's CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen... ► Artikel lesen | |
ARVINAS | 41,100 | -0,96 % | Arvinas Inc.: Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |